Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies

Internal Medicine Journal

Volumn 42, Issue 3, 2012, Pages 252-259

  Bleasel, K ^a   Heddle, R ^d   Hissaria, P ^e   Stirling, R ^b   Stone, C ^c   Maher, D ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c CSL LIMITED   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Agammaglobulinaemia; Antibody deficiency syndrome; Immunoglobulin; Intragam 10 NF; Pharmacokinetics

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVITIS; CONSTIPATION; COUGHING; CROSSOVER PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HOT FLUSH; HUMAN; IMMUNE DEFICIENCY; INFECTION; LETHARGY; MALAISE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PAIN; PNEUMONIA; PRIMARY IMMUNODEFICIENCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAMIN D DEFICIENCY; WHEEZING;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; AUSTRALIA; CROSS-OVER STUDIES; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84858728731     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02712.x     Document Type: Article

References (29)

1. Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents 2011; 37: 396-404.
2. Shehata N. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010; 24 (Suppl 1): 28-50.
3. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA etal. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117 (Suppl 4): S525-53.
4. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010; 98: 12-28.
5. ® P. Australian approved product information. 2007 [cited 2011 October 31] CSL Limited. Available from URL:.
6. Spaeth P, Van Holten RW. Pathogen safety of immunoglobulin preparations. In: Wahn V, Orange J, eds. Clinical Use of Immunoglobulins. Bremen: Uni-Med Science; 2008; 40.
7. Bertolini J. Chromatographic purification of immunoglobulins. Downstream 1999; 31: 20-1.
8. Johnston A, Adcock W. The use of chromatography to manufacture purer and safer plasma products. Biotechnol Genet Eng Rev 2000; 17: 37-70.
9. ® 10 NF. Australian approved product information. 2011 [cited 2011 October 31] CSL Limited. Available from URL:.
10. Caress J, Burton L, Eickman K. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf 2010; 9: 971-9.
11. Stucki M, Boschetti N, Schäfer W, Hostettler T, Käsermann F, Nowak T etal. Investigations of prion and virus safety of a new liquid IVIg product. Biologicals 2008; 36: 239-47.
12. ® virus removal filters. Biologicals 2001; 29: 17-25.
13. Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13: 320-8.
14. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). CPMP/BPWG/388/95 rev.1; June 2000. [cited 2010 June 23] Available from:.
15. Wasserman RL, Church JA, Peter HA, Sleasman JW, Melamed I, Stein MR etal. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci 2009; 37: 272-8.
16. ®, 10%). Vox Sang 2003; 84: 202-10.
17. Wolf HH, Davies SV, Borte M, Caulier MT, Williams PE, Bernuth HV etal. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003; 84: 45-53.
18. ® 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004; 24: 309-14.
19. Borte M, Davies SV, Touraine JL, Farber CM, Lipsic T, Adams C etal. Clinical properties of a novel liquid intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Transfus Med Hemother 2004; 31: 126-34.
20. ® 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004; 24: 389-96.
21. Matamoros N, De Gracia J, Hernández F, Pons J, Álvarez A, Jiménez V. A prospective controlled crossover trial of a new presentation (10% vs 5%) of a heat-treated intravenous immunoglobulin. Int Immunopharmacol 2005; 5: 619-26.
22. Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC etal. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26: 388-95.
23. ®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patents with primary immunodeficiencies. J Clin Immunol 2009; 29: 137-44.
24. Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 2006; 26: 813-27.
25. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28: 803-19.
26. Orange J. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137: 21-30.
27. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years. J Allergy Clin Immunol 2010; 125: 1354-60.
28. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C etal. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011; 31: 315-22.
29. Scott M. Comparison of intravenous immunoglobulin formulations: product, formulary, and cost considerations. Hosp Pharm 2011; 46: 668-76.